What is the maintenance dose of semaglutide after weight loss?

What the Label Actually Says

Wegovy's FDA labeling calls for titration up to 2.4 mg weekly, and that dose is intended to be ongoing. The trials didn't test lower maintenance doses after weight loss; they just kept participants at 2.4 mg for the duration of the studies.

The concept of a "maintenance dose" lower than 2.4 mg is off-label clinical practice, not FDA-endorsed protocol. Whether it works is still being actively studied.

The Case for a Lower Maintenance Dose

• Side effects (GI, nausea, fatigue) often persist at full dose
• Monthly cost at 2.4 mg maintenance is significant even for compounded
• Mechanism suggests lower dose may be sufficient to prevent regain since the body isn't still actively losing
• SURMOUNT-4 tirzepatide data showed that dose withdrawal caused significant regain, supporting ongoing dosing but not necessarily at maximum

The Case Against a Lower Maintenance Dose

• STEP 1 extension data: participants who continued 2.4 mg kept most of their weight loss at 2 years
• STEP 4 showed that switching 2.4 mg to placebo after 20 weeks caused ~65% regain in 48 weeks
• Lower doses may allow gradual regain because appetite suppression is dose-dependent
• Titrating down and then back up again can restart the side effect curve

Typical Clinical Maintenance Doses in Practice

What telehealth clinics and metabolic/obesity medicine practices commonly use post-goal:

• 0.5 mg weekly: lowest practical maintenance; some patients hold weight, some gradually regain
• 1.0 mg weekly: common middle-ground maintenance dose
• 1.7 mg weekly: closer to therapeutic range but below max
• 2.4 mg weekly: continuing full dose; safest for weight retention
• 2.4 mg every 2 weeks: "extended interval" dosing; emerging practice, limited data

How to Step Down

If you and your provider decide to reduce dose, the typical approach:

1. Reach goal weight and hold for 2–3 months at full dose to stabilize
2. Drop one titration step (e.g., 2.4 → 1.7 mg)
3. Monitor weight weekly for 6 weeks
4. If weight holds within 3–5 lbs, drop again
5. If weight creeps up, return to previous dose

Don't step down faster than every 4–6 weeks. The half-life is ~1 week, so dose changes take 4–5 weeks to reach new steady state.

Why the 3–5 lb Threshold

Water weight and daily variability easily explain 3–5 lb swings. If you dropped dose and see a 2 lb gain after 4 weeks, that's noise. If you see an 8 lb gain after 4 weeks, that's signal. Use body weight trend over 2–3 weeks, not any single measurement.

Alternatives to Dose Reduction

• Longer dosing interval at same dose: 2.4 mg every 10 days instead of weekly. Reduces monthly cost and total exposure. Limited published data but widely practiced.
• Pulse dosing: 4–8 week off periods followed by retitration. Generally not recommended; appetite and weight return aggressively during off periods.
• Switch to lower-potency GLP-1: liraglutide (Saxenda) is daily and shorter-acting; some patients transition off semaglutide entirely via liraglutide

Indefinite Low-Dose: Is It Safe?

Best available data comes from type 2 diabetes use, where patients have taken semaglutide at lower doses (0.5–1.0 mg) for years without safety signal issues. No published data on indefinite use at weight-loss doses beyond 2–3 years. The theoretical risk list (thyroid, pancreas) is the same at any dose.

What to Discuss With Your Provider

• What weight target does "maintenance" mean for you — goal weight or a range?
• What's your side effect burden at current dose?
• Is cost a factor in wanting to reduce dose?
• What's the plan if weight creeps back?
• How long has your weight been stable before stepping down?

Bottom Line

There's no single right answer on maintenance dose. Clinically, 1.0–1.7 mg weekly is common and appears to work for many patients, but the evidence base is thinner than for 2.4 mg. Work with a provider who can step you down deliberately and rescue the dose if regain starts.

See the semaglutide guide. Related: stopping semaglutide rebound, plateau on semaglutide.